Results 231 to 240 of about 293,301 (286)

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi   +12 more
wiley   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro   +17 more
wiley   +1 more source

A comparison of strategies for selecting auxiliary variables for multiple imputation. [PDF]

open access: yesBiom J
Mainzer RM   +5 more
europepmc   +1 more source

Multiple imputation integrated to machine learning: predicting post-stroke recovery of ambulation after intensive inpatient rehabilitation. [PDF]

open access: yesSci Rep
Finocchi A   +11 more
europepmc   +1 more source

Comparison of common multiple imputation approaches: An application of logistic regression with an interaction. [PDF]

open access: yesRes Methods Med Health Sci
Smith MJ   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy